参考文献: Canon, J. et al. The clinical KRAS(G12C) inhibitor AMG 510 drives anti- tumour immunity. Nature 575, 217–223 (2019) Hallin, J. et al. The KRASG12C inhibitor, MRTX849, provides insight toward therapeutic susceptibility of KRAS mutant cancers in mouse models and patients. Canc...
参考文献: Canon, J. et al. The clinical KRAS(G12C) inhibitor AMG 510 drives anti- tumour immunity. Nature 575, 217–223 (2019) Hallin, J. et al. The KRASG12C inhibitor, MRTX849, provides insight toward therapeutic susceptibility of KRAS mutant cancers in mouse models and patients. Canc...
1.Sanchez-Vega, F.et al. Cell173, 321–337 (2018). 2.Canon, J.et al. Nature575, 217–223 (2019). 3. Lu,S., Jang, H., Nussinov, R. & Zhang, J.Sci. Rep.6, 21949 (2016). 4.AACR Project GENIE Consortium.Cancer Discov.7, 818–831 (2017). 5.Herbst, R. S., Morgenszt...
Canon, J. et al. The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity.Nature575, 217–223 (2019). ArticleADSCASPubMedGoogle Scholar
Nature 575, 217–223 (2019). CAS PubMed Google Scholar Mirati Therapeutics. Mirati Therapeutics Presents First Clinical Data of Phase 1/2 Trial of MRTX849 at the 2019 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics ir.mirati.com https://ir.mirati.com/news...
575 1,069 24,271 7,260 41,941 17,362 115,635 7,962 7,268 21,948 12,755 2,667 1,660 1,008 12,120 8,820 7,096 3,321 15,579 11,801 874 1,362 399 8,204 13,936 3,436 5,918 5,816 5,816 4,124 2,376 3.582 3.581 3.581 3.580 3.579 3.577 3.575 3.574 3.574 3.573 3.573...
Madinina2017-by-Lugdivine-Unfer-635 Madinina2017-by-Lugdivine-Unfer-628 Madinina2017-by-Lugdivine-Unfer-623 Madinina2017-by-Lugdivine-Unfer-605 Madinina2017-by-Lugdivine-Unfer-586 Madinina2017-by-Lugdivine-Unfer-575 首页| 前页| 1 2 | 下一页 | 最后 技术...
We read every piece of feedback, and take your input very seriously. Include my email address so I can be contacted Cancel Submit feedback Saved searches Use saved searches to filter your results more quickly Cancel Create saved search Sign in Sign up Reseting focu...
S187\L217和Q319可能对在存在icFSP1的情况下触发细胞中相分离的FSP1–FSP1相互作用具有关键作用。从概念上讲,icFSP1可能通过直接或间接涉及残基如S187、L217和Q319的相互作用来调节FSP1的相变、改变相边界。特别是,肉豆蔻酰化可能是该过程中不可或缺的,icFSP1作为配体会优先结合肉豆蔻酰形式的FSP1。综上,icF...
Nature 575, 217–223 (2019). Article CAS PubMed Google Scholar Liao, W. et al. KRAS-IRF2 axis drives immune suppression and immune therapy resistance in colorectal cancer. Cancer Cell 35, 559–572 e557 (2019). Article CAS PubMed PubMed Central Google Scholar Dang, C. V. MYC on ...